GLP-1 Medications and Smoking Cessation: What the Research Shows

Introduction

The link between GLP-1 medications and smoking cessation started, like so much of this drug class's story, with patients saying something their doctors didn't expect. People on semaglutide (Ozempic, Wegovy) for weight or blood sugar kept reporting that cigarettes had simply lost their pull — the same way the drugs quiet the urge to eat. That anecdote has now been chased into real data, and the early picture is intriguing: GLP-1 receptor agonists may blunt nicotine cravings and, just as importantly, neutralize the weight gain that drives so many ex-smokers back to the pack.

Smoking remains the leading preventable cause of death in the United States, and roughly two-thirds of people who smoke say they want to quit. Yet existing cessation aids help only a minority succeed, and one of the most powerful saboteurs is the scale: most people gain weight after quitting, and the fear of that gain keeps many smoking. A drug that addresses both the craving and the weight is exactly the kind of two-for-one that could change the math. This is what the research actually shows about GLP-1 medications and smoking cessation — where the signal is strong, where it is still thin, and what to make of it today.

The Weight-Gain Trap That Keeps Smokers Smoking

To understand why this drug class drew attention for tobacco at all, start with the problem cessation medicine has never solved well: nicotine suppresses appetite and nudges metabolism upward, so quitting reliably triggers weight gain. The average ex-smoker puts on several pounds in the first year, and a meaningful subset gains far more. For many — especially women and people already carrying excess weight — that prospect is a deal-breaker, and relapse often traces directly back to it.

Every first-line cessation aid, from nicotine replacement to varenicline to bupropion, targets the craving but does little to stop the post-quit weight creep. That is the gap GLP-1 drugs are uniquely positioned to fill, because suppressing appetite and lowering body weight is precisely what they were built to do. The same machinery that dampens the food noise that GLP-1 drugs are known to silence appears to reach the reward circuitry that nicotine hijacks — meaning one molecule might address both halves of the trap at once.

How GLP-1 Receptors Reach the Brain's Reward System

The biological rationale is more than hand-waving. GLP-1 receptors are not confined to the gut and pancreas — they are scattered through the brain, including the mesolimbic dopamine pathway, the same reward circuit that nicotine, alcohol, and other addictive substances exploit to make their use feel rewarding.

Evidence: "Treatment with Exendin-4, at a dose with no effect per se, attenuated nicotine-induced locomotor stimulation, accumbal dopamine release, as well as the expression of conditioned place preference in mice." — Egecioglu E, Engel JA, Jerlhag E. PLoS One. 2013. DOI: 10.1371/journal.pone.0077284

In plain terms, a GLP-1 drug blunted the dopamine surge that nicotine produces in the brain's reward center — the very surge that makes smoking reinforcing. Animals stopped finding nicotine as rewarding. A body of preclinical work has since reproduced and extended that finding across different models and agents.

Evidence: "Preclinical studies consistently demonstrate that GLP-1 receptor agonists reduce nicotine intake and nicotine-seeking behavior through modulation of mesolimbic dopamine signaling, an effect that in some cases persists beyond drug exposure." — Herman RJ, Schmidt HD. Physiology & Behavior. 2024. DOI: 10.1016/j.physbeh.2024.114565

This shared reward-pathway mechanism is also why the same drug class is being studied for GLP-1 medications and alcohol use and the broader question of GLP-1 drugs and addiction. Nicotine is simply one of several substances that route through the dopamine system these medications seem to turn down.

What the Human Data Shows on Smoking Cessation

Mouse studies open a door; they don't walk through it. The most consequential human evidence so far comes from a large analysis of real-world health records that asked a sharp question: among people who both smoke and have type 2 diabetes, does starting semaglutide change their tobacco-related medical care compared with starting a different diabetes drug?

Evidence: "Among 222,942 patients with type 2 diabetes and tobacco use disorder, new use of semaglutide was associated with a significantly lower risk of medical encounters for tobacco use disorder and fewer prescriptions for smoking-cessation medications compared with seven other antidiabetes drugs." — Wang W, et al. Annals of Internal Medicine. 2024;177(8):1016-1027. DOI: 10.7326/M23-2718

Three details make this study hard to dismiss. First, the effect held even when semaglutide was compared against other GLP-1 receptor agonists, hinting that semaglutide's brain penetration may matter. Second, the reduction in tobacco-related care emerged within 30 days of starting treatment — fast enough to suggest a direct pharmacological effect rather than a slow downstream consequence of weight loss. Third, the association was similar whether or not patients had obesity, which weakens the explanation that the benefit is just about losing weight.

The Randomized Trial Signal

Observational data, however large, can only show association. The strongest causal evidence to date comes from a small but genuinely randomized trial that added a GLP-1 drug to standard nicotine patches.

Evidence: "Exenatide adjunct to the nicotine patch produced a 7-day point-prevalence abstinence rate of 46.3% versus 26.8% with placebo (risk ratio 1.70), while post-cessation body weight was approximately 5.6 pounds lower in the exenatide group." — Yammine L, et al. Nicotine & Tobacco Research. 2021;23(10):1682-1690. DOI: 10.1093/ntr/ntab066

This pilot, in 82 prediabetic or overweight smokers, is the proof-of-concept the field needed: adding a GLP-1 drug nearly doubled the quit rate and reversed the usual post-quit weight gain in the same patients. It is small and short, but it points in exactly the direction the mechanism and the cohort data predict.

A 2024 systematic review pulled the threads together across populations, including people with psychiatric conditions, who smoke at far higher rates and quit far less often.

Evidence: "Across eight studies — five preclinical and three clinical involving 594 participants — GLP-1 receptor agonists showed promise for nicotine use disorder by targeting smoking behavior, craving, withdrawal, and post-cessation weight gain, with the weight-gain benefit absent from existing approved cessation aids." — Lee S, et al. Annals of General Psychiatry. 2024;23:45. DOI: 10.1186/s12991-024-00527-9

Here is how the major human findings line up:

Study / population	Design	Key result
Wang 2024 (222,942 smokers with T2D)	Target trial emulation, real-world data	Lower tobacco-care risk vs 7 diabetes drugs; effect within 30 days
Yammine 2021 (82 smokers, overweight/prediabetic)	Randomized controlled trial	Abstinence 46.3% vs 26.8% (RR 1.70); ~5.6 lb less weight gain
Lee 2024 systematic review (594 clinical participants)	Review of 8 studies	Consistent signal for craving, withdrawal, and weight control

The Double Benefit That Sets GLP-1 Drugs Apart

What distinguishes GLP-1 medications from every other cessation tool is not necessarily a higher raw quit rate — varenicline remains the most effective standalone aid — but the package. Nicotine replacement, bupropion, and varenicline all leave the weight-gain problem untouched. A drug that suppresses cravings while also preventing or reversing post-quit weight gain attacks the single most common reason people relapse.

That combination could be especially valuable for the patients who need it most: those with obesity, type 2 diabetes, or metabolic syndrome, for whom both continued smoking and added weight compound cardiovascular risk. For someone already considering a GLP-1 medication for weight management, a reduced pull toward cigarettes would be a meaningful bonus rather than the reason for the prescription. The flip side of GLP-1 weight effects — protecting lean tissue during loss — is covered in our look at GLP-1 drugs and muscle loss, and the same appetite-and-reward biology underlies both.

What the Evidence Cannot Yet Tell You

The enthusiasm has to be tempered by what is still missing, because the gaps are real.

The decisive trials are not finished. Almost all the human evidence is observational, drawn from people who happened to be prescribed these drugs for diabetes or weight — not from smokers randomized specifically to quit. The one randomized trial is a small pilot. Large, purpose-built cessation trials are now underway, including a multi-site study of tirzepatide for smoking cessation (NCT07602699) and a randomized trial of semaglutide for limiting post-cessation weight gain (NCT06173778), but their results are years away.

Most data comes from people with diabetes or obesity. Whether the same benefit extends to smokers of normal weight without metabolic disease is unknown. The biology suggests it should, but suggestion is not proof.

No GLP-1 drug is approved or recommended for smoking cessation. Using one off-label to quit smoking is not currently supported by guidelines, and these medications carry their own side-effect profile — nausea, gastrointestinal upset, and rare but serious risks — that has to be weighed against proven, lower-cost cessation aids.

The honest summary: the mechanism is plausible, the early human data points consistently in one direction, and the weight-control angle is a genuine advance no existing cessation drug offers. But until the randomized trials report, GLP-1 medications belong in the category of promising and unproven for this use — not standard care.

Key Takeaways

GLP-1 receptors sit in the brain's mesolimbic dopamine reward pathway, the same circuit nicotine exploits; preclinical studies show GLP-1 drugs blunt nicotine's dopamine surge and reduce nicotine-seeking.
A 2024 Annals of Internal Medicine analysis of 222,942 smokers with type 2 diabetes linked semaglutide to lower tobacco-related medical care than seven other diabetes drugs, with effects appearing within 30 days and independent of obesity.
A randomized pilot trial found that adding exenatide to nicotine patches raised abstinence from 26.8% to 46.3% and cut post-cessation weight gain by about 5.6 pounds.
The standout advantage is the double benefit: GLP-1 drugs may curb cravings and prevent the post-quit weight gain that drives relapse — something no approved cessation aid does.
The evidence is mostly observational and concentrated in people with diabetes or obesity; large randomized cessation trials of tirzepatide and semaglutide are ongoing but not yet reported.
No GLP-1 medication is approved for smoking cessation. Proven aids like varenicline remain first-line, and any GLP-1 use for quitting today is off-label and unproven.

References

Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes: Target Trial Emulation Using Real-World Data. Annals of Internal Medicine. 2024;177(8):1016-1027. DOI: 10.7326/M23-2718
Yammine L, Green CE, Kosten TR, et al. Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial. Nicotine & Tobacco Research. 2021;23(10):1682-1690. DOI: 10.1093/ntr/ntab066
Egecioglu E, Engel JA, Jerlhag E. The Glucagon-Like Peptide 1 Analogue Exendin-4 Attenuates the Nicotine-Induced Locomotor Stimulation, Accumbal Dopamine Release, Conditioned Place Preference as well as the Expression of Locomotor Sensitization in Mice. PLoS One. 2013;8(10):e77284. DOI: 10.1371/journal.pone.0077284
Herman RJ, Schmidt HD. Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence. Physiology & Behavior. 2024;281:114565. DOI: 10.1016/j.physbeh.2024.114565
Lee S, Roy A, Sahota S, et al. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review. Annals of General Psychiatry. 2024;23:45. DOI: 10.1186/s12991-024-00527-9

Last updated: 2026-06-22 Medical review: Dr. James Chen, MD, PhD, FACE